Induction of antinuclear antibodies in patients with rheumatoid arthritis receiving treatment with human recombinant interferon gamma.
AUTOR(ES)
Seitz, M
RESUMO
Of six patients with rheumatoid arthritis (RA) treated with human recombinant interferon gamma for two to eight months, three developed antinuclear antibodies (ANAs). This was accompanied by a simultaneous clinical exacerbation of the disease activity. In this study both anti-inflammatory and immunostimulatory effects of human recombinant interferon gamma in patients with RA were observed.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1006714Documentos Relacionados
- Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study.
- Decreased level of antibodies against Helicobacter pylori in patients with rheumatoid arthritis receiving intramuscular gold.
- Association of HLA-B35 with mucocutaneous lesions in Israeli patients with rheumatoid arthritis receiving gold treatment.
- Increase in neutrophil Fc gamma receptor I expression following interferon gamma treatment in rheumatoid arthritis.
- Response of anaemia in rheumatoid arthritis to treatment with subcutaneous recombinant human erythropoietin.
